A
14.57
-0.38 (-2.54%)
| Previous Close | 14.95 |
| Volume | 386,928 |
| Price / Sales | 6.23 |
| Price / Book | 1.83 |
| 52 Weeks Range |
| Profit Margin | 16,556.01% |
| Operating Margin (TTM) | -11,408.39% |
| Diluted EPS (TTM) | 118.98 |
| Quarterly Revenue Growth (YOY) | -66.40% |
| Total Debt/Equity (MRQ) | 0.65% |
| Current Ratio (MRQ) | 22.61 |
| Operating Cash Flow (TTM) | -52.31 M |
| Levered Free Cash Flow (TTM) | -238.14 M |
| Return on Assets (TTM) | -23.98% |
| Return on Equity (TTM) | 678.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Avalo Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
-1.4
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -0.5 |
| Average | -1.43 |
|
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.39% |
| % Held by Institutions | 76.24% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |